Revance will wait to seek backing for Botox-rival

(Reuters) - Revance Therapeutics Inc will wait to seek partnerships with bigger drugmakers until it is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.